Fluticasone/salmeterol

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Retrieved on: 
Tuesday, June 6, 2023
Software, Pharmaceutical, Data Management, IOT (Internet of Things), Apps, Applications, Technology, Medical Devices, Health Technology, Health Insurance, Biotechnology, Wearables, Mobile Technology, Practice Management, Health, Hypersensitivity, Anti-inflammatory, Salbutamol, Angioedema, Rash, Pain, Contraindication, Prednisone, Adrenal insufficiency, Digital health, Patient, Risk, Common, SVP, Arrhythmia, Hyperthyroidism, Wheeze, Physician, Urinary tract infection, Innovation, ICS, Measles, Hypertension, Vomiting, Back pain, System, Anaphylaxis, Trauma, Death, Moyamoya disease, Sinusitis, Allergy, Fungus, Fever, Eye, Hypokalemia, Record, Parasitism, Chickenpox, Medicine, LABA, Hives, Tuberculosis, Immune system, Milk, Heart rate, Bronchoconstriction, Blood pressure, Infection, Teva Pharmaceuticals, Gastroenteritis, Partnership, Diabetes, Tricyclic, Simplex, EMR, Fatality, Respiratory disease, Inc., Itch, Lactose, Bronchospasm, Immunosuppression, Fluticasone/salmeterol, Pharmaceutical industry, Generic drug, Vaccine, Medical device, Asthma

The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.

Key Points: 
  • The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.
  • Using the PhilRx Patient Access Platform, patients can fill their prescription, review prescription records and obtain assistance navigating insurance benefits.
  • The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting when the physician writes the prescription.
  • Physicians can select the PhilRx Patient Access Platform directly from an electronic medical record (EMR) to submit a prescription for a Digihaler product.

Respiratory Inhalers Market Report 2023-2033

Retrieved on: 
Tuesday, January 3, 2023
Organization, Drug class, Table, Mouth, NCBI, Dry-powder inhaler, ICS, Mode, Government, Chronic obstructive pulmonary disease, Asthma, Growth, Recession, COVID-19, CDC, Region, Medicare, SAMA, LAMA, Degenerative disease, Perception, Immunity, COPD, Prevalence, Throat, Market, SABA, LABA, Pulmonary hypertension, Spirometry, Data analysis, Pharmaceutical industry, Liquor, Fossil fuel, Marketing, Oil, Fluticasone/salmeterol

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Forecasts by Product Type (Standard Pressurised Metered-Dose Inhalers, Pressurised Metered-dose Inhalers, Metered-Dose Inhaler with a Spacer, Dry Powder Inhalers, Soft Mist Inhalers, Others), by Drug Class (ICS, SABA+ICS, SABA, LABA, LAMA, ULABA, SABA+SAMA, LABA+LAMA+ICS, SAMA, Others), by Mode of Operation (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices, Others), by Indication (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

Key Points: 
  • • Where is the respiratory inhalers market heading and how can you ensure you are at the forefront of the market?
  • You need to discover how this will impact the respiratory inhalers market today, and over the next 10 years:
    • Our 354-page report provides 126 tables and 184 charts/graphs exclusively to you.
  • This report tells you TODAY how the respiratory inhalers market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce.
  • • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising respiratory inhalers prices and recent developments.

LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

Retrieved on: 
Thursday, July 29, 2021
Chemical compounds, Health care, Health sciences, Muscarinic antagonists, Boehringer Ingelheim, Bromides, Epoxides, Thiophenes, Tiotropium bromide, Abbreviated New Drug Application, Inhaler

PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.

Key Points: 
  • PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
  • U.S. sales of Spiriva Handihaler were $1.5 billion for the 12 months ending May, 2021 according to IQVIA, although actual generic market values are expected to be lower.
  • "With generic Spiriva Handihaler, our strategic relationship with Respirent now includes three inhaler products, each of which has the potential to be a meaningful contributor to our company's financial performance.
  • The generic Spiriva Handihaler product is currently in development and tracking to Abbreviated New Drug Application (ANDA) submission in 2023."

Hikma resumes launch of generic Advair Diskus®

Retrieved on: 
Tuesday, April 20, 2021
Fluticasone/salmeterol, Health care, Life sciences, Health

For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.

Key Points: 
  • For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.
  • We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines.
  • We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.
  • For more information, please visit: www.hikma.com\n1Advair and Advair Diskus are registered trademarks of GSK group of companies.\n"

Lannett Submits ANDA For Generic ADVAIR DISKUS®

Retrieved on: 
Thursday, April 1, 2021
Health care, Drugs, Health, Respiratory therapy, Glucocorticoids, Combination drugs, Fluticasone/salmeterol, Salmeterol, Organofluorides, Dosage forms, Fluticasone propionate, GlaxoSmithKline

The product is the generic equivalent of ADVAIR DISKUS of GlaxoSmithKline.

Key Points: 
  • The product is the generic equivalent of ADVAIR DISKUS of GlaxoSmithKline.
  • "The ANDA submission of generic ADVAIR DISKUS marks a significant advancement toward our goal of adding larger and more durable products to our portfolio," said Tim Crew, chief executive officer of Lannett.
  • "Currently, our agreements with Respirent include generic Advair Diskus, as well as second powder inhaler product, generic Flovent Diskus (Fluticasone Propionate Powder Inhaler).
  • As previously announced, Lannett entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS (Fluticasone Propionate Salmeterol Xinafoate Powder Inhaler) of Respirent.

Hikma launches generic Advair Diskus® following FDA approval

Retrieved on: 
Thursday, December 17, 2020
Drugs, Clinical medicine, Glucocorticoids, Health care, Respiratory therapy, Combination drugs, Fluticasone/salmeterol, Salmeterol, Organofluorides, Pregnanes, Fluticasone propionate, Fluticasone

Do not use fluticasone propionate and salmeterol inhalation powder if you have a severe allergy to milk proteins.

Key Points: 
  • Do not use fluticasone propionate and salmeterol inhalation powder if you have a severe allergy to milk proteins.
  • Do not use fluticasone propionate and salmeterol inhalation powder if you are allergic to fluticasone propionate, salmeterol or any of the ingredients in fluticasone propionate and salmeterol inhalation powder.
  • Rinse your mouth with water without swallowing after each dose of fluticasone propionate and salmeterol inhalation powder.
  • 1Advair and Advair Diskus are registered trademarks of GSK group of companies.

Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio

Retrieved on: 
Wednesday, October 21, 2020
Technology, Mobile, Wireless, Software, Networks, Managed care, Health, Pharmaceutical, General Health, Data management, Physical sciences, Chemistry, RTT, Branches of biology, Asthma, Bronchospasm, Dietary minerals, Fluticasone/salmeterol, Breathing, Potassium, Salmeterol

If you have sudden breathing problems immediately after inhaling your medicine, stop using AIRDUO DIGIHALER and call your healthcare provider right away.

Key Points: 
  • If you have sudden breathing problems immediately after inhaling your medicine, stop using AIRDUO DIGIHALER and call your healthcare provider right away.
  • You should have regular eye exams while using AIRDUO DIGIHALER or ARMONAIR DIGIHALER.
  • For AIRDUO DIGIHALER, changes may occur in laboratory blood values (sugar, potassium, certain types of white blood cells)
    For ARMONAIR DIGIHALER increased wheezing (bronchospasm) may occur.
  • Additionally, AIRDUO DIGIHALER has common side effects of:
    ARMONAIR DIGIHALER has common side effects of:
    These are not all the possible side effects of AIRDUO DIGIHALER and ARMONAIR DIGIHALER.

Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma

Retrieved on: 
Monday, October 5, 2020
Respiratory therapy, Clinical medicine, Pulmonology, Health care, Glucocorticoids, RTT, Organofluorides, Pregnanes, Asthma, Fluticasone propionate, Fluticasone, Fluticasone/salmeterol

Aermony RespiClick (fluticasone propionate inhalation powder) is packaged in an innovative device with features designed to simplify the administration of inhaled therapy and reduce patient error and confusion.

Key Points: 
  • Aermony RespiClick (fluticasone propionate inhalation powder) is packaged in an innovative device with features designed to simplify the administration of inhaled therapy and reduce patient error and confusion.
  • With this innovative method of delivery of medication, respirologists and asthma patients will experience the simplified administration features the RespiClick device has to offer," said Christine Poulin, general manager of Teva Canada.
  • "Aermony RespiClick is a meaningful expansion of our offerings in respirology, which currently include both proprietary and generic products."
  • Aermony RespiClick is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older.

Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder

Retrieved on: 
Monday, September 21, 2020
General Health, Pharmaceutical, Health, Health care, Health, Clinical medicine, Respiratory therapy, RTT, Glucocorticoids, Dosage forms, Asthma, Inhaler, Salmeterol, Fluticasone/salmeterol, Fluticasone propionate

Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AirDuo Digihaler (fluticasone propionate and salmeterol) inhalation powder and ArmonAir Digihaler (fluticasone propionate) inhalation powder, two digital maintenance inhalers for patients with asthma.

Key Points: 
  • Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AirDuo Digihaler (fluticasone propionate and salmeterol) inhalation powder and ArmonAir Digihaler (fluticasone propionate) inhalation powder, two digital maintenance inhalers for patients with asthma.
  • AirDuo Digihaler and ArmonAir Digihaler are not used to relieve sudden breathing problems from asthma and will not replace the need for a rescue inhaler.
  • The AirDuo Digihaler and ArmonAir Digihaler inhalers automatically detect, record and store objective inhaler use data, including peak inspiratory flow.
  • AIRDUO DIGIHALER and ARMONAIR DIGIHALER are not used to relieve sudden breathing problems from asthma and won't replace a rescue inhaler.

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

Retrieved on: 
Friday, June 5, 2020
Chemical compounds, Drugs, Organic compounds, RTT, Combination drugs, Muscarinic antagonists, Glucocorticoids, Indacaterol, Respiratory therapy, Mometasone, Salmeterol, Fluticasone/salmeterol

Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.

Key Points: 
  • Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.
  • These data show the potential of this novel combination product as an effective and convenient therapy in patients with uncontrolled asthma.
  • Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
  • Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.